Received Jan 14, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| PNC20 | PNEUMO (PREVNAR20) | PFIZER\WYETH | UNK | — | — |
| PPV | PNEUMO (PNEUMOVAX) | MERCK & CO. INC. | UNK | — | — |
Physician noted that no symptomatic events were seen or reported. No additional AE/No PQC reported.; Physician reported that PNEUMOVAX-23 and PREVNAR-20 were both administered to a 3 year old patient with sickle cell.; This spontaneous report was received from a physician and refers to a 3-year-old patient of unknown gender. The patient's concurrent conditions included sickle cell. The patient medical history, concomitant therapies, previous drugs reactions and allergies were not reported. On 19-Dec-2025, the patient was vaccinated with pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX 23), injection, administered as prophylaxis (Lot No., expiration date, strength, dose number, exact dose quantity volume, route and anatomical location of administration and vaccination scheme frequency were not provided); also with pneumococcal vaccine conj 20v (crm197)) (PREVNAR 20) (Lot No., expiration date, strength, dose number, exact dose quantity volume, route and anatomical location of administration, indication and vaccination scheme frequency were not provided) (extra dose administered). No symptomatic events were seen or reported. No additional AE (no adverse event). Lot number is being requested and will be submitted if received.
Sickle cell disorders